Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 26 May 2018
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.
- 11 Oct 2017 Planned End Date changed from 31 Jul 2020 to 30 Sep 2020.
- 11 Oct 2017 Planned primary completion date changed from 31 Jul 2020 to 30 Sep 2020.